Sign up
Pharma Capital

ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research

Andrew Newland, chief executive of ANGLE plc (LON:AGL), tells Proactive London's Andrew Scott their cancer detection device has played an important role in research that may one day help prevent the spread of cancer around the body.

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters - a group of cancer and other cells tethered together as a single mass.

Once these clusters were identified, the Basel team, led by Professor Nicola Aceto, was able to treat them with repurposed drugs already on the market.


View full AGL profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.